Ovascience Cmn Stk (OVAS) 5.09 $OVAS
OvaScience to Present at the JMP Securities Life Sciences Conference
BusinessWire - Fri Jun 17, 7:00AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 11:30 am ET at the St. Regis New York.
OVAS: 5.09 (-0.27)
OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Fri Jun 03, 3:05PM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement award to its newly appointed Executive Vice President, Human Resources, Toni Spinazzola. The award was approved by the Board's Compensation Committee on June 1, 2016 and ratified by the full Board on June 2, 2016 as an inducement material to her entering into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4). The inducement grant to Ms. Spinazzola consisted of an option to purchase up to 100,000 shares of common stock. The inducement grant is exercisable at a price of $7.30 per share, equal to the closing price per share of OvaScience's common stock as reported by NASDAQ on June 1, 2016. The stock options vest over four years, with 25% of the shares vesting on May 16, 2017 and an additional 6.25% of the shares vesting at the end of each subsequent quarter thereafter, subject to Ms. Spinazzola's continued service relationship with OvaScience through the applicable vesting dates.
OVAS: 5.09 (-0.27)
OvaScience Announces Closing of Public Offering of Common Stock
BusinessWire - Wed Jun 01, 3:05PM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the closing of its previously announced public offering, including the exercise in full by the underwriters of their option to purchase an additional 1,072,500 shares of common stock at the public offering price of $7.00 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by OvaScience to 8,222,500 shares and increased the total net proceeds raised in this offering to $53.8 million, after deducting underwriting discounts and commissions and estimated expenses. OvaScience intends to use the proceeds from this offering to fund the commercial expansion of the AUGMENT(SM) treatment in its key regions, Japan and Canada, the ongoing pre-commercial activities for the OvaPrime(SM) treatment and the OvaTure(SM) treatment, and working capital and other general corporate purposes.
OVAS: 5.09 (-0.27)
OvaScience Announces Pricing of Public Offering of Common Stock
BusinessWire - Thu May 26, 7:00AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it has priced its previously announced underwritten public offering of 7,150,000 shares of its common stock at a public offering price of $7.00 per share. Net proceeds to OvaScience from this offering are expected to be approximately $46.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. OvaScience intends to use the proceeds from this offering to fund the commercial expansion of the AUGMENT(SM) treatment in its key regions, Japan and Canada, the ongoing pre-commercial activities for the OvaPrime(SM) treatment and the OvaTure(SM) treatment, and working capital and other general corporate purposes.
OVAS: 5.09 (-0.27)
OvaScience Announces Proposed Public Offering of Common Stock
BusinessWire - Wed May 25, 3:30PM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it has commenced an underwritten public offering of shares of its common stock. OvaScience intends to grant the underwriters a 30-day option to purchase additional shares of the common stock to cover over-allotments, if any. All of the shares in the offering will be sold by OvaScience.
OVAS: 5.09 (-0.27)
OvaScience Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 3:00PM CDT
---- New research supports AUGMENT and pipeline treatments--
OVAS: 5.09 (-0.27)
Kite (KITE) to Report Q1 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Wed May 04, 9:59AM CDT
With no approved products in its portfolio, investor focus will be primarily on Kite's (KITE) cash burn and pipeline updates.
OVAS: 5.09 (-0.27), KITE: 52.06 (-1.05), JAZZ: 141.12 (-3.88), AMGN: 148.98 (-3.29)
Juno (JUNO) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 8:17AM CDT
With no approved products in its portfolio, investor focus will remain on Juno's (JUNO) pipeline progress and cash burn.
OVAS: 5.09 (-0.27), JAZZ: 141.12 (-3.88), JUNO: 42.02 (-1.68), CELG: 98.38 (-2.28)
Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 5.09 (-0.27), JAZZ: 141.12 (-3.88), VVUS: 1.10 (unch), ARNA: 1.82 (-0.09)
Repros (RPRX) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:25AM CDT
With no approved products in its portfolio, investors will be focused on Repros' progress with its pipeline candidates as well as its cost projections.
OVAS: 5.09 (-0.27), JAZZ: 141.12 (-3.88), RPRX: 1.57 (-0.13), CHMA: 2.68 (-0.06)
Geron (GERN) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:20AM CDT
Investor focus will remain on pipeline updates from Geron (GERN).
JNJ: 116.60 (-0.78), OVAS: 5.09 (-0.27), GERN: 2.65 (-0.10), JAZZ: 141.12 (-3.88)
OvaScience to Host First Quarter 2016 Financial Results Conference Call
BusinessWire - Thu Apr 28, 3:00PM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. EDT on Thursday, May 5, 2016 to discuss first quarter 2016 financial results and provide a general corporate update.
OVAS: 5.09 (-0.27)
OvaScience Announces Senior Management Changes and Appointments
BusinessWire - Thu Mar 31, 6:00AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Arthur Tzianabos, Ph.D., has stepped down as President and Chief Scientific Officer to assume the role of Chief Executive Officer at an early stage biotechnology company. In order to facilitate an orderly transition, Dr. Tzianabos will consult for the Company until the end of the year. James D. Luterman, Ph.D., OvaScience's Vice President, Research & Development, has been appointed the role of Senior Vice President, Research & Development and will report directly to Michelle Dipp, M.D., Ph.D., Executive Chair and Chief Executive Officer of OvaScience.
OVAS: 5.09 (-0.27)
Stocks That Require Your Attention In 3/21/16 Trading Session
ACCESSWIRE - Mon Mar 21, 12:34PM CDT
MIAMI, FL / ACCESSWIRE / March 21, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. SZYM, OVAS, HGSH, and CUBA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
OVAS: 5.09 (-0.27), HGSH: 1.76 (-0.07), CUBA: 6.00 (-0.19), SZYM: 2.15 (+0.02)
CoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of Directors
GlobeNewswire - Tue Mar 15, 7:00AM CDT
CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches in adults, announced today that Alison Lawton, has been elected by the Board of Directors to serve as a director. Ms. Lawton will serve as a class I director of the Company with a term expiring at the annual meeting of stockholders to be held in 2016. In addition, Ms. Lawton has been appointed to the Company's Audit Committee. CoLucid's Board remains at seven directors, six of whom are independent.
CBSTZ: 0.06 (unch), CLCD: 6.66 (-0.06), OVAS: 5.09 (-0.27)
OvaScience to Present at Cowen and Company Health Care Conference
BusinessWire - Mon Mar 07, 6:00AM CST
OvaScience(SM) (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 at 8:00 a.m. ET at the Boston Marriott Copley Place in Boston, MA.
OVAS: 5.09 (-0.27)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against OvaScience, Inc. - OVAS
BusinessWire - Wed Feb 10, 3:02PM CST
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of OvaScience, Inc. securities (NASDAQ:OVAS) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with OvaScience's January 8, 2015 Secondary Offering (the "Offering"
. The lawsuit seeks to recover damages for OvaScience investors under the federal securities laws.
OVAS: 5.09 (-0.27)
Robbins Arroyo LLP: OvaScience, Inc. (OVAS) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Mon Feb 08, 6:58PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed in the Suffolk County Superior Court for the Commonwealth of Massachusetts. The complaint alleges that officers and directors of OvaScience, Inc. (NASDAQGM: OVAS) violated the Securities Act of 1933 in connection with the company's January 8, 2015 Secondary Offering (the "Offering" when they sold 2.3 million shares of common stock at an offering price of $50.00 per share. OvaScience is a life science company that develops and markets new treatments for infertility. Its AUGMENT treatment, designed to improve the health of the woman's eggs, is available in certain in vitro fertilization ("IVF" clinics in select international regions.
OVAS: 5.09 (-0.27)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of OvaScience, Inc. -- OVAS
GlobeNewswire - Wed Feb 03, 5:04PM CST
Levi & Korsinsky announces it has commenced an investigation of OvaScience, Inc. (NASDAQ:OVAS) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
OVAS: 5.09 (-0.27)
OvaScience to Present at the JMP Securities Life Sciences Conference
BusinessWire - Fri Jun 17, 7:00AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 11:30 am ET at the St. Regis New York.
OVAS: 5.09 (-0.27)
OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Fri Jun 03, 3:05PM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement award to its newly appointed Executive Vice President, Human Resources, Toni Spinazzola. The award was approved by the Board's Compensation Committee on June 1, 2016 and ratified by the full Board on June 2, 2016 as an inducement material to her entering into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4). The inducement grant to Ms. Spinazzola consisted of an option to purchase up to 100,000 shares of common stock. The inducement grant is exercisable at a price of $7.30 per share, equal to the closing price per share of OvaScience's common stock as reported by NASDAQ on June 1, 2016. The stock options vest over four years, with 25% of the shares vesting on May 16, 2017 and an additional 6.25% of the shares vesting at the end of each subsequent quarter thereafter, subject to Ms. Spinazzola's continued service relationship with OvaScience through the applicable vesting dates.
OVAS: 5.09 (-0.27)
OvaScience Announces Closing of Public Offering of Common Stock
BusinessWire - Wed Jun 01, 3:05PM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the closing of its previously announced public offering, including the exercise in full by the underwriters of their option to purchase an additional 1,072,500 shares of common stock at the public offering price of $7.00 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by OvaScience to 8,222,500 shares and increased the total net proceeds raised in this offering to $53.8 million, after deducting underwriting discounts and commissions and estimated expenses. OvaScience intends to use the proceeds from this offering to fund the commercial expansion of the AUGMENT(SM) treatment in its key regions, Japan and Canada, the ongoing pre-commercial activities for the OvaPrime(SM) treatment and the OvaTure(SM) treatment, and working capital and other general corporate purposes.
OVAS: 5.09 (-0.27)
OvaScience Announces Pricing of Public Offering of Common Stock
BusinessWire - Thu May 26, 7:00AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it has priced its previously announced underwritten public offering of 7,150,000 shares of its common stock at a public offering price of $7.00 per share. Net proceeds to OvaScience from this offering are expected to be approximately $46.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. OvaScience intends to use the proceeds from this offering to fund the commercial expansion of the AUGMENT(SM) treatment in its key regions, Japan and Canada, the ongoing pre-commercial activities for the OvaPrime(SM) treatment and the OvaTure(SM) treatment, and working capital and other general corporate purposes.
OVAS: 5.09 (-0.27)
OvaScience Announces Proposed Public Offering of Common Stock
BusinessWire - Wed May 25, 3:30PM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it has commenced an underwritten public offering of shares of its common stock. OvaScience intends to grant the underwriters a 30-day option to purchase additional shares of the common stock to cover over-allotments, if any. All of the shares in the offering will be sold by OvaScience.
OVAS: 5.09 (-0.27)
OvaScience Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 3:00PM CDT
---- New research supports AUGMENT and pipeline treatments--
OVAS: 5.09 (-0.27)
Kite (KITE) to Report Q1 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Wed May 04, 9:59AM CDT
With no approved products in its portfolio, investor focus will be primarily on Kite's (KITE) cash burn and pipeline updates.
OVAS: 5.09 (-0.27), KITE: 52.06 (-1.05), JAZZ: 141.12 (-3.88), AMGN: 148.98 (-3.29)
Juno (JUNO) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 8:17AM CDT
With no approved products in its portfolio, investor focus will remain on Juno's (JUNO) pipeline progress and cash burn.
OVAS: 5.09 (-0.27), JAZZ: 141.12 (-3.88), JUNO: 42.02 (-1.68), CELG: 98.38 (-2.28)
Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 5.09 (-0.27), JAZZ: 141.12 (-3.88), VVUS: 1.10 (unch), ARNA: 1.82 (-0.09)
Repros (RPRX) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:25AM CDT
With no approved products in its portfolio, investors will be focused on Repros' progress with its pipeline candidates as well as its cost projections.
OVAS: 5.09 (-0.27), JAZZ: 141.12 (-3.88), RPRX: 1.57 (-0.13), CHMA: 2.68 (-0.06)
Geron (GERN) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:20AM CDT
Investor focus will remain on pipeline updates from Geron (GERN).
JNJ: 116.60 (-0.78), OVAS: 5.09 (-0.27), GERN: 2.65 (-0.10), JAZZ: 141.12 (-3.88)
OvaScience to Host First Quarter 2016 Financial Results Conference Call
BusinessWire - Thu Apr 28, 3:00PM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. EDT on Thursday, May 5, 2016 to discuss first quarter 2016 financial results and provide a general corporate update.
OVAS: 5.09 (-0.27)
OvaScience Announces Senior Management Changes and Appointments
BusinessWire - Thu Mar 31, 6:00AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Arthur Tzianabos, Ph.D., has stepped down as President and Chief Scientific Officer to assume the role of Chief Executive Officer at an early stage biotechnology company. In order to facilitate an orderly transition, Dr. Tzianabos will consult for the Company until the end of the year. James D. Luterman, Ph.D., OvaScience's Vice President, Research & Development, has been appointed the role of Senior Vice President, Research & Development and will report directly to Michelle Dipp, M.D., Ph.D., Executive Chair and Chief Executive Officer of OvaScience.
OVAS: 5.09 (-0.27)
Stocks That Require Your Attention In 3/21/16 Trading Session
ACCESSWIRE - Mon Mar 21, 12:34PM CDT
MIAMI, FL / ACCESSWIRE / March 21, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. SZYM, OVAS, HGSH, and CUBA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
OVAS: 5.09 (-0.27), HGSH: 1.76 (-0.07), CUBA: 6.00 (-0.19), SZYM: 2.15 (+0.02)
CoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of Directors
GlobeNewswire - Tue Mar 15, 7:00AM CDT
CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches in adults, announced today that Alison Lawton, has been elected by the Board of Directors to serve as a director. Ms. Lawton will serve as a class I director of the Company with a term expiring at the annual meeting of stockholders to be held in 2016. In addition, Ms. Lawton has been appointed to the Company's Audit Committee. CoLucid's Board remains at seven directors, six of whom are independent.
CBSTZ: 0.06 (unch), CLCD: 6.66 (-0.06), OVAS: 5.09 (-0.27)
OvaScience to Present at Cowen and Company Health Care Conference
BusinessWire - Mon Mar 07, 6:00AM CST
OvaScience(SM) (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 at 8:00 a.m. ET at the Boston Marriott Copley Place in Boston, MA.
OVAS: 5.09 (-0.27)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against OvaScience, Inc. - OVAS
BusinessWire - Wed Feb 10, 3:02PM CST
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of OvaScience, Inc. securities (NASDAQ:OVAS) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with OvaScience's January 8, 2015 Secondary Offering (the "Offering"
. The lawsuit seeks to recover damages for OvaScience investors under the federal securities laws. OVAS: 5.09 (-0.27)
Robbins Arroyo LLP: OvaScience, Inc. (OVAS) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Mon Feb 08, 6:58PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed in the Suffolk County Superior Court for the Commonwealth of Massachusetts. The complaint alleges that officers and directors of OvaScience, Inc. (NASDAQGM: OVAS) violated the Securities Act of 1933 in connection with the company's January 8, 2015 Secondary Offering (the "Offering"
when they sold 2.3 million shares of common stock at an offering price of $50.00 per share. OvaScience is a life science company that develops and markets new treatments for infertility. Its AUGMENT treatment, designed to improve the health of the woman's eggs, is available in certain in vitro fertilization ("IVF" clinics in select international regions. OVAS: 5.09 (-0.27)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of OvaScience, Inc. -- OVAS
GlobeNewswire - Wed Feb 03, 5:04PM CST
Levi & Korsinsky announces it has commenced an investigation of OvaScience, Inc. (NASDAQ:OVAS) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
OVAS: 5.09 (-0.27)
